Skip to main content

Drug Interactions between erdafitinib and niraparib

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Minor

niraparib erdafitinib

Applies to: niraparib and erdafitinib

Coadministration of niraparib with a P-glycoprotein (P-gp) and/or Breast Cancer Resistance Protein (BCRP) inhibitor may increase the plasma concentration of niraparib, which is a substrate of these efflux transporters. However, due to the high permeability and bioavailability of niraparib, the risk of a clinically relevant interaction with inhibitors of these transporters is unlikely. No dose adjustment is recommended if a P-gp and/or BCRP inhibitor is added to treatment with niraparib.

References

  1. "Product Information. Akeega (abiraterone-niraparib)." Janssen Biotech, Inc. (2023):
  2. "Product Information. Zejula (niraparib)." GlaxoSmithKline (2023):
  3. "Product Information. Zejula (niraparib)." GlaxoSmithKline Inc (2023):
  4. "Product Information. Akeega (abiraterone-niraparib)." Janssen Inc (2023):
  5. "Product Information. Zejula (niraparib)." GlaxoSmithKline Australia Pty Ltd (2023):
  6. "Product Information. Zejula (niraparib)." GlaxoSmithKline UK Ltd (2023):
View all 6 references

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer